Drawing for Serial No. 97819622

USPTO serial 97819622

Serial No. 97819622

Reviewed by CopyMark Law Group

Reg. 7770900Status 700Registered
Filing date
Status date
Registration date
Apr 22, 2025
Examiner
THOMA, GABRIELLE M
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 97819622?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Ryan D. Artis

Ryan D. Artis RIVERSIDE LAW LLP175 STRAFFORD AVESUITE 100WAYNE, PA 19087

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic test kits consisting primarily of medical diagnostic immunoassays and complementary diagnostic reagents for testing of bodily fluids for use in detection of human diseases, namely, breast cancer, for clinical medical testing and medical useACTIVE—
042Biotechnology research and development; Medical research and development in the field of cancer, inflammatory diseases, and psychological maladies; Scientific research and development; Medical and scientific research services in the field of diagnostic tests for cancer, inflammatory diseases, and psychological maladies; Medical laboratoriesACTIVE—
044Providing medical screening services for cancer and inflammatory diseases, and psychological maladies; Medical screening; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical screening using protein biomarkers; Medical screening using RNA and DNA biomarkers; Medical screening service in the field of tear testing for breast health screeningACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 22, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Apr 22, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 2, 2025SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Apr 2, 2025CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Mar 16, 2025SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Mar 16, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jan 14, 2025IUAFUSE AMENDMENT FILED—
Jan 14, 2025EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jul 16, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 21, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 21, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 1, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 17, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 12, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 12, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 12, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 1, 2024XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Mar 1, 2024XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Dec 1, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 1, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 1, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 30, 2023DOCKASSIGNED TO EXAMINER—
Mar 23, 2023MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Mar 22, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 6, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance